Medivir appoints John Öhd as Chief Medical Officer
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that John Öhd, MD, PhD has been appointed as its new Chief Medical Officer.“I am pleased to appoint John Öhd, currently clinical R&D head, to the newly created position of Chief Medical Officer, reporting to me” says CEO, Christine Lind. “With the broad clinical pipeline that Medivir has, it is important for us to have an executive leader in this position. John’s unique and broad experiences as a drug developer, clinician and experimental scientist make him an exceptional choice for this role on Medivir’s Executive